Brainsway

A global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Health Tech & Life Sciences
Public on TASE on Jan, 2007
Public on NASDAQ on Apr, 2019
Public Jerusalem, Israel Founded 2003
Last updated 2026-09-06
Total raised
$98.5M
Last: Debt Financing 2026-03
Stage
Public
Founded
2003
Headcount
129
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

BrainsWay is a global medical technology company focused on developing cutting-edge medical devices that help advance the field of mental healthcare. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology is used for the non-invasive treatment of major depressive disorder (including reduction of anxiety symptoms), obsessive-compulsive disorder (OCD), and smoking addiction. The company's technology is based on patents filed by the U.S. National Institutes of Health (NIH) and by the company, holding an exclusive license from the NIH for the patent and its technology. BrainsWay's Deep TMS system has received FDA clearance for these indications and CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions.

Funding history · 6 rounds · $98.5M total

8 events/rounds · $98.5M Total Funding: $8.5M in Private Equity, $126.7M in Public Equity
May 2025
Follow-on PO $14.3M EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2021
Follow-on PO $39.3M EDGAR filing SEC-EDGAR filing SEC-EDGAR
Apr 2019
Follow-on PO $27.5M EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2014
B Round Undisclosed tracxn.com
Jan 2007
Follow-on PO $8.9M sec.gov ↗

Headcount over time

129 employees (2026-09) · 1 point
129 129 2026-09

Offices

Jerusalem, Israel · HQ / main office
Show all offices (1 more)
  • Burlington, United States

Q&A

What was BrainsWay's most recent funding event?
BrainsWay completed a Public Offering in May 2025.
When did BrainsWay last raise debt financing, and for what amount?
BrainsWay's last debt financing occurred in March 2026, raising $6,000,000.
What is BrainsWay's current employee count?
BrainsWay has 51-200 employees.
What was the total amount of funding BrainsWay has raised to date?
BrainsWay has raised a total of $89,367,000.
When did BrainsWay receive FDA clearance for its Deep TMS 360™ System for Alcohol Use Disorder?
BrainsWay launched its first clinical trial for the Deep TMS 360™ System for Alcohol Use Disorder in November 2025, but the data does not specify an FDA clearance date for this indication.
What was a significant operational highlight for BrainsWay in the first quarter of 2025?
BrainsWay reported its first quarter 2025 financial results and operational highlights in May 2025.
Has BrainsWay made any recent strategic investments?
In May 2026, BrainsWay announced a minority-stake investment in Hopemark Health.
What was a key development for BrainsWay in September 2025 regarding its Deep TMS protocol?
In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for the non-invasive treatment of Major Depressive Disorder (MDD).
What was a notable achievement for BrainsWay in November 2025 concerning adolescent depression treatment?
In November 2025, BrainsWay received FDA clearance of Deep TMS™ as an adjunct therapy for Major Depressive Disorder (MDD) in adolescents aged 15 to 21.

Team · 25

Avner Hagai
Founder · Independent Director
David Zacut
Founder · Co-Founder & Vice-Chairman
Yiftach Roth
Founder · Chief Scientific Officer
Abraham Zangen
Founder · Co-Founder, Member of Scientific Advisory Board & Director
Hadar Levy
Chief Executive Officer
Ido Marom
Chief Financial Officer
Gilead Moiseyev
Chief Technology Officer
Naomi Rozenfeld
Chief Marketing Officer
Moria Ben Soussan (Ankri)
Vice President of Research & Development
Michael Cohen
Vice President of US Sales
Colleen Hanlon
Vice President of Medical Affairs
Menachem C. Klein
VP, General Counsel and Corporate Secretary
Dor Hagai
Vice President of Operations
Nurit Tsur Lev
VP Commercial & Business Development
Richard A. Bermudes
Chief Medical Officer
Amiram Boehm
Independent Chairman
Eti Mitrany
Independent Director
Karen Sarid
Independent Director
Avner Lushi
Independent Director
Jonathan K. Shulkin
Independent Director
Mark S. George
Member of the Scientific Advisory Board
David Feifel
Member of the Scientific Advisory Board
Mark Hallett
Member of the Scientific Advisory Board
Zafiris Daskalakis
Member of the Scientific Advisory Board
Markus Heilig
Member of Scientific Advisory Board

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers

Highlights

1 Patents

Tags

neuro-stimulationchronic-painnon-invasivepsychiatryneurologymental-healthmedical-devicesparkinsonalzheimers-diseasebrain-disorderhospitalsclinicshealthcare-providersmedical-technologiestreatmentspatients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitebrainsway.com
LinkedInlinkedin.com/company/3253269
Facebookfacebook.com/BrainswayDeepTMS
YouTubeyoutube.com/channel/UCGcpxh6bCwWr76SCItRpyvw
Instagraminstagram.com/brainsway
Wikipediaen.wikipedia.org/wiki/Brainsway
Wikidatawikidata.org/wiki/Q2913953

Identifiers & details

Legal nameBrainsWay Ltd.
Founded2003
Employees (exact)129
OfficesBurlington
Market cap$372.4M
Status reasonPublic on TASE on Jan, 2007; Public on NASDAQ on Apr, 2019
Wikidata QIDQ2913953

Acquisitions & public offerings

TypeDateExchangeTickerAmount
IPO2007-01TASEBRIN$9.3M
IPO2019-04NASDAQBWAY$27.5M

Radar intelligence

Patents

EPO19

Publications (Crossref)

Works10

Web history (Wayback)

Domainbrainsway.com

Wikidata

QIDQ2913953

Certificate / subdomain footprint

Subdomains32

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)513890764
Statusפעילה
Corp typeישראלית חברה ציבורית
Incorporated2006-11-07
Purposeלעסוק בסוגי עיסוק שפורטו בתקנון
Liabilityמוגבלת
In violation (unfiled)no
Active charges / liens0
Registry events1 — violation (1)
Registered addressהרטום 16 ירושלים

Recent registry events

DateEvent
2026-06-01עדכון הפרה